ArticleJournal of neuro-oncology2012
p53 expression predicts dismal outcome for medulloblastoma patients with metastatic disease.
Article in Journal of neuro-oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Article
- Regulation of Chemosensitivity in Human Medulloblastoma Cells by p53 and the PI3 Kinase Signaling Pathway.Molecular cancer research : MCR · 2022Article
- Modulating native GABAJournal of neuro-oncology · 2019Article
- Sophoridine suppresses cell growth in human medulloblastoma through FoxM1, NF-κB and AP-1.Oncology letters · 2017Article
- Medulloblastoma: molecular pathways and histopathological classification.Archives of medical science : AMS · 2016Article
- The WIP1 oncogene promotes progression and invasion of aggressive medulloblastoma variants.Oncogene · 2015Article
- Wnt activation affects proliferation, invasiveness and radiosensitivity in medulloblastoma.Journal of neuro-oncology · 2015Article
- WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma.Acta neuropathologica communications · 2014Article
- MYCN amplification predicts poor outcome for patients with supratentorial primitive neuroectodermal tumors of the central nervous system .Neuro-oncology · 2014Article
- Neuroradiology and histopathology in two cases of adult medulloblastoma.The neuroradiology journal · 2014Article
- The rationale for targeted therapies in medulloblastoma.Neuro-oncology · 2014Review
- Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2013Article
- Optimizing drug development of anti-cancer drugs in children using modelling and simulation.British journal of clinical pharmacology · 2013Review
- HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment.Journal of neuro-oncology · 2012Article
- Prognostic value of the TP53 Arg72Pro single-nucleotide polymorphism and susceptibility to medulloblastoma in a cohort of Brazilian patients.Journal of neuro-oncology · 2012Article
- Loss of TP53 expression in immortalized choroid plexus epithelial cells results in increased resistance to anticancer agents.Journal of neuro-oncology · 2012Article
- Molecular subgroups of medulloblastoma.Expert review of neurotherapeutics · 2012Review
- HDM2 promotes WIP1-mediated medulloblastoma growth.Neuro-oncology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medulloblastoma (MB) is the most common malignant primary brain tumour in childhood. Metastatic disease (M+) at diagnosis is the most important negative prognostic clinical marker and, despite craniospinal irradiation and intensive chemotherapy, it remains one of the leading causes of treatment failure. To date, few clinical and biological data have been evaluated to obtain an additional prognostic profile for these high-risk patients. In this study, 169 patients with metastatic MB registered in the multicentre HIT2000 trial of the German Society of Pediatric Oncology and Haematology (GPOH) have been investigated to determine the importance of p53 protein expression in predicting survival. At a median follow-up of 4.1 years, 159 patients with p53-negative tumours had significantly better four-year event-free survival (EFS) and progression-free survival (PFS) (56 ± 11, 59 ± 4%) than 10 patients with p53-positive tumours (40 ± 16, 40 ± 16%; P = 0.018 for EFS, P = 0.007 for PFS, respectively). Furthermore, four-year overall survival (OS) of children with p53-negative tumours was higher than for children with p53-positive tumours (72 ± 4 vs. 35 ± 18%, P = 0.05). Three of the p53-positive MBs harbored a point mutation in the TP53 gene. p53 protein assessment by immunohistochemistry may be a useful tool for sub-stratification of metastatic high-risk MB patients.
Indexed as
Identifiers
21796446What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.